Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland

• Published in: Journal of personalized medicine Vol. 12; no. 3; p. 441
• Main Authors: Reymann, Stephan, Schoretsanitis, Georgios, Egger, Stephan T, Mohonko, Alexey, Kirschner, Matthias, Vetter, Stefan, Homan, Philipp, Seifritz, Erich, Burrer, Achim
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 11.03.2022; MDPI
• Subjects: antipsychotic; Antipsychotics; Aripiprazole; Comorbidity; depot; Drug use; Health care; Hospitalization; Length of stay; long-acting injectable; Medical records; Mental disorders; Meta-analysis; Palmitic acid; Patients; Precision medicine; Psychiatry; Psychotropic drugs; Risperidone; schizoaffective; Schizophrenia; schizophrenia spectrum disorder; Substance abuse treatment; Trends; United States > US; Switzerland; New York City New York; schizophrenia spectrum disorder; long-acting injectable; depot; inpatient; prescribing pattern; antipsychotic; schizoaffective; schizophrenia
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm12030441

Long-acting injectable antipsychotics (LAIs) offer many benefits to patients with schizophrenia spectrum disorder (SSD). They are used with very different frequencies due to questions of eligibility or patients and prescribers' attitudes towards LAI use. We assessed the prescribing rates of LAIs in a large academic psychiatric hospital with a public service mandate in Switzerland and compared them with other countries and health care systems. To our knowledge, this study is the first to investigate inpatient LAI use in Europe. Medical records of all patients diagnosed with SSD discharged from the Clinic of Adult Psychiatry of the University Hospital of Psychiatry Zurich over a 12 month period from January to December 2019 were evaluated regarding the prescribed antipsychotics at the time of discharge. The rates of use of LAIs among all patients and among patients receiving LAI-eligible antipsychotic substances were assessed retrospectively. We assessed records of 885 patients with SSD. Among all cases, 13.9% received an LAI. Among patients who received antipsychotic medication that was eligible for LAI use ( = 434), 28.1% received an agent as an LAI. LAI use included paliperidone palmitate (69.9%), aripiprazole monohydrate (14.6%), risperidone (4.9%) and first-generation LAIs (9.8%). Compared to international frequencies of LAI administration, the prescription rate of LAIs in SSD patients was low. Further studies will evaluate patient- and prescriber-related reasons for this low rate.